CQS Cayman’s Orexigen Therapeutics, Inc. OREX Stock Holding History

CQS Cayman’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-11,300	Closed	-$38K	–	155
2016 Q3	$38K	Hold	11,300	–	–	﹤0.01%	138
2016 Q2	$49K	Hold	11,300	–	–	﹤0.01%	130
2016 Q1	$64K	Sell	11,300 -32,500	-74%	-$422K	0.01%	103
2015 Q4	$753K	Sell	43,800 -80,000	-65%	-$1.91M	0.05%	113
2015 Q3	$2.61M	Sell	123,800 -11,200	-8%	-$384K	0.22%	78
2015 Q2	$6.68M	Sell	135,000 -47,200	-26%	-$2.82M	0.4%	63
2015 Q1	$14.3M	Buy	182,200 +7,200	+4%	+$447K	0.67%	31
2014 Q4	$10.6M	Hold	175,000	–	–	0.71%	37
2014 Q3	$7.46M	Buy	175,000 +108,996	+165%	+$5.85M	0.44%	56
2014 Q2	$4.08M	Buy	+66,004	New	+$3.84M	0.25%	67

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

OWIM

Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

CQS Cayman's OREX Position: Q4 2016 in Review

CQS Cayman sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2016, closing a stake of 11,300 shares — an estimated $38K sold.

CQS Cayman first reported a position in OREX in Q2 2014 and held it in 10 quarters. The position peaked at $14.3M in Q1 2015. 53 funds tracked by Wall St. Rank hold OREX as of Q4 2016.

CQS Cayman reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
CQS Cayman sold 11,300 Orexigen Therapeutics, Inc. shares in Q4 2016, an estimated $38K.
CQS Cayman first reported a position in Orexigen Therapeutics, Inc. in Q2 2014 and held it in 10 quarters.
CQS Cayman's Orexigen Therapeutics, Inc. position peaked at $14.3M in Q1 2015.
53 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2016.

Based on CQS Cayman's 13F filing for Q4 2016, filed 14 Feb 2017.